# SULFACETAMIDE SODIUM, SULFUR- sulfacetamide sodium, sulfur cloth KMM Pharmaceuticals, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

-----

## Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleansing Cloths

## **Rx Only**

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

#### **DESCRIPTION:**

Each cloth is coated with a cleanser-based formulation. Each gram of solution contains 98 mg of sodium sulfacetamide and 48 mg of colloidal sulfur in a vehicle consisting of: benzyl alcohol, cetyl alcohol, fragrance, glyceryl stearate (and) PEG-100 stearate, magnesium aluminum silicate, phenoxyethanol, propylene glycol, purified water, sodium lauryl sulfate, sodium magnesium silicate, sodium thiosulfate, stearyl alcohol and xanthan gum.

Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Sodium sulfacetamide is C  $_8$ H  $_9$ N  $_2$ NaO  $_3$ S·H  $_2$ O with molecular weight of 254.24. Chemically, sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:

Sodium sulfacetamide is an odorless, white, crystalline powder with a bitter taste. It is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform and in ether.

#### **CLINICAL PHARMACOLOGY:**

Sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide sensitive Grampositive and Gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic infections. It acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with para-aminobenzoic acid. There is no clinical data available on the degree and rate of systemic absorption of this product when applied to the skin or scalp. However, significant absorption of sodium sulfacetamide through the skin has been reported.

The following in vitro data is available but the clinical significance is unknown. Organisms that show susceptibility to sodium sulfacetamide are: Streptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, Salmonella species, Proteus vulgaris, Nocardia and Actinomyces.

The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of *Propionibacterium acnes* and the formation of free

fatty acids.

#### **INDICATIONS AND USAGE:**

This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

#### **CONTRAINDICATIONS:**

This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. This product is not to be used by patients with kidney disease.

#### **WARNINGS:**

Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. **KEEP OUT OF THE REACH OF CHILDREN.** 

#### **PRECAUTIONS:**

#### FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

**General:** Nonsusceptible organisms, including fungi, may proliferate with the use of this preparation.

Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. If the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved. Systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. Under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed.

The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

**Information for Patients:** Patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere.

The use of this product also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop. Avoid contact with eyes, lips and mucous membranes.

**Drug Interactions:** This product is incompatible with silver preparations.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on this product to date. Studies on reproduction and fertility also have not been performed. Chromosomal nondisjunction has been reported in the yeast, Saccharomyces cerevisiae, following application of sodium sulfacetamide. The significance of this finding to the topical use of sodium sulfacetamide in the human is unknown.

**Pregnancy:**Category C. Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.

**Pediatric Use:** Safety and effectiveness in children under the age of 12 years have not been established.

#### **ADVERSE REACTIONS:**

Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).

#### **OVERDOSAGE:**

The oral LD  $_{50}$  of sulfacetamide in mice is 16.5 g/kg. In the event of overdosage, emergency treatment should be started immediately.

**Manifestations:** Overdosage may cause nausea and vomiting. Large oral overdosage may cause hematuria, crystalluria and renal shutdown due to the precipitation of sulfa crystals in the renal tubules and the urinary tract. For treatment, contact your local Poison Control Center or your doctor.

#### **DOSAGE AND ADMINISTRATION:**

Wash affected areas with this product once or twice daily or as directed by a physician. Moisten skin and cleansing cloth with water. Work cloth into full lather and massage gently into skin for 10 to 20 seconds, rinse thoroughly and pat dry. Discard cloth in refuse container. If drying occurs, it may be controlled by rinsing affected area sooner or using product less frequently.

#### **STORAGE:**

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized.

**NOTICE:** Protect from freezing and excessive heat. The product may tend to darken slightly on storage. Slight discoloration does not impair the efficacy or safety of the product.

Occasionally, a slight discoloration of fabric may occur when an excessive amount of the product is used and comes in contact with white fabrics. This discoloration, however, presents no problem, as it is readily removed by ordinary laundering without bleaches.

#### **HOW SUPPLIED:**

60 count carton, **NDC** 52187-552-60

**To report** a serious adverse event or obtain product information, call 1-855-899-4237.

#### Manufactured for:

KMM Pharmaceuticals, LLC 1000 N. West Street Suite 1200, #1201 Wilmington, DE 19801 2100567 [00] Rev. 09/2021

WARNINGS: Suffoundeds are known to cause Stewers-Johnson syndrome is hyperserality individuals. Stewers-Johnson syndrome also has been reported following the use of soften collecteralities topically. Sease of stray-indeed systemic lapse enythernations from topical suffacetancies also have been reported, in one of these cases, there was no fall outcomer. KEEP OUT OF EASON OF CHALLOWS.

PRECAUTIONS: FOR EXTERNAL USE ONLY, NOT FOR OPHTHALMIC USE. Do not use IT

Conoral: Nonsusceptible organisms, including fungi, may proliferate with the use of this

Although rare, penaltivity to sodium suffacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical suifonamides. If the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. Patients should be carefully observed for possible local initiation or sensitization during Problem involution destinating statement for processe soon intraction or remarkation suring large-from thereopy. Systemic stoom chacitions such as apprecisioposes, social behavioral exercise, purpose hermanispica, drug fiver, juunidec and contact dermatitis indicate hippertermitifity is sufferentiates. Perfluction causities should be employed? If writes of dermated or absorbed side are involved. Systemic absorption of stupical subtomerables in proster infollowing application to large, inclinical, sended, directable or anxiety lumined arises. Under these circumstances, any of the adverse which produced by the systemic administration of letter appretix could plantishly occur, and appropriate observations and laboratory determinations should be performed.

The object of this therapy is to solvieve desquarantion without inflation, but sodium sufficient and outer endouring and souting of the opidemis. These side effects are not unusual in the breatment of acree vulgate, but patients should be outloosed about the possibility.

Information for Patients: Patients should discontinue the use of this product if the intermation for Patients include discontinue the use of the product is to condition becomes worse or if a nosh develops in the area being treated or elsewhere. The use of this product also should be elseonthroad promptly and the physician notified if any arthritis, fever or some in the mosth develop. Avoid contact with eyes, lips and

Drug Interactions: This product is incompetible with silver preparations.

Carcinogenesis. Mutagenesis and impairment of Fertility: Larg-form estimal studies for carchopenic potential have not been performed on this product to date. Studies on reproduction and refilty size have not been performed. Chromosomal mondistunction has been reported in the yeast Saccharanges cerediste, following application of solidon estimations. The significance of this finding to the topical use of scalum surfaces with the topical use of scalum surfaces.

Pregnancy: Category C. Animal reproduction studies have not been conducted with this groutest. It is also not known whether this product can affect reproduction capacity or ourse fetch harm when administered to a pregnant women. This product should be used by a pregnant warman only if clearly needed or when potential benefits ortherely potential hazards to the fetus.

Nursing Methers: It is not known whether this drug is excelled in human mile. Be many drugs are exceeded in human milk, caution should be exercised when this pr is administered to a nursing woman.

(continued on side punel)

Pediatric Use: Salety and effectiveness in children under the agr of 12 years have not been extablished.

ACMERSE REACTIONS: Reports of inflation and hypersensitivity to sockum suffacetamine are uncommon. The following adverse mactions, reported after administration of stelle spitthalmic sodium suffacetamide, are notiverably. Instances of Stevers-Johnson syndrome and instances of local hypersensitivity which progress to a syndrome resembling systemic lupus erythematicsus; in one case a fatal outcome was reported (see WWMMSG).

OVERDOSAGE: The stal LD<sub>N</sub> of outbootsmide in mice is 16.5 g/kg. in the event of overdosage, emergency treatment should be sto

Large oral overdoxage may cause hemisturis, snystaturis and renal shutdown due to the percipitation of sufficiently in the renal studies and the urbany tract. For the threat, contact your local Poison Control Center or your doctor.

DISABLE AND ADMINISTRATION: Which affected areas with this product once or twice dialty or an elevated by a physician. Moisten soin and obesiden joich with water. Work coich into full either and ministege gently this old for 10 to 20 seconds, from bettings, the soin of 10 to 20 seconds, from the product of the product o

STORAGE: Store at 20°C to 25°C 68°F to 77°F. Stormach: Storm in 20°C to 25°C (persons 55°C and 86°C), description permitted between 15°C and 30°C (persons 55°C and 86°C), Brief exposure to temperature up to 40°C (104°C), may be tolerated exposure to temperature sizes not exceed 25°C (72°C), however, such exposure should be milimized.

HOTICE: Protect from freezing and excessive heat. The product may tend to darken elightly on elonge. Slight discoloration does net impair the efficacy or safety of the product.

Occasionally, a slight discoloration of fidure may occur when an excessive amount of the product is used and comes in confact with white fabrics. This discolaration, however, prevents no problem, as it is readily removed by ordinary laundering without bleaches.

HOW SUPPLIED: 60 count carton, NDC 52187-552-60

Manufactured for NMM Pramiscruticals, LLC 1900 N. West Street Suits 1200, 41921 Wilmington, DE 19801 2190687 [00] Rev. 09/2021



NDC 52187-552-60

Rx Only

## Sodium Sulfacetamide 9.8% and Sulfur 4.8%

**Cleansing Cloths** 

60 Cleansing Cloths (Net Wt. 4 g each)

Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleansing Cloths

FOR EXTERNAL USE ONLY, NOT FOR OPHTHALMIC USE.

DESCRIPTION: Each olds is coasted with a cleanine-based formulation. Each grain of volution contains 98 mg of sodium sufficienties and 48 mg of existing sodium sodium and a sufficient of the most allocation of the most allocation, profit solicity, fragancies, glyceny feature (and PGD-190 steams), pragression aluminum allocation phenosystemic, progression plant set of sodium lossyst solicity, sodium librium magnesium silicate, sodium librium magnesium silicate, sodium litrium magnesium silicate, sodium litrium tragensium silicate, sodium litrium magnesium silicate, sodium silicate sodium silic xanthan gum.

Sodium sufficetamide is a sufferamide with antibacterial activity while sufur acts or a lorentsylvic agent. Sodium sufficetamile in Cataly, NaO(3-11; O with molecular weight of 254.24. Chemically, addium sulf-cetamile in N-10-aminophron) suffany(-actamide, monocodium suft, monalryshafe. The structural formula in:

Sodium outlacetamide is an odorieus, white, crystalline powers with a bitter taste. It is freely soluble in water, sparlingly soluble in alcohol, while gractically involuble in benome, in chloratorm and in effect

write practically involuble in bindines, in chloroform and in other CLUMCAL PRACHAGORY, Social subtractantial creative creeks a binchritectatic state against subtramental creative form-partitive and Gram-regulative microorganisms commonly included from secondary columnate propertic infections. It acts by practicities to epithesis of folio asid propined by bacteria for growth, by its competition with pare-eministences asid, there is no official data available on the expert and not of systemic absorption of this product when applied to the risks or scale, thousand, state absorption of sodium subtractantide through the skin has been reported.

The following in vitro data is available but the clinical significance is unknown. Organisms that show susceptibility to sodium suffacetamide are Streptonocci, Staphylococci, E. coli, Klebsiella pneumonise, Pseudomonas pycoyanes, Salmonella species Proteus vulgaris, Hocardia and Astinomyces.

The exact mode of action of suitor in the treatment of acre is unknown, but it has been reported that it inhibits the growth of Propionibucterium acress and the formation of thee failty acids.

INDICATIONS: This product is indicated for use in the topical control of some valgate, some rowaces and velocities derivatile.

CONTRANDICATIONS: This product is contained cated in persons with income or suspected hypersonsitivity to any of the ingredients of the product. This product is not to be used by patients with idoney (lieses, (continued on back panel)

## SULFACETAMIDE SODIUM, SULFUR

sulfacetamide sodium, sulfur cloth

#### **Product Information**

**HUMAN PRESCRIPTION DRUG** NDC:52187-552 **Product Type** Item Code (Source) **Route of Administration TOPICAL** 

### Active Ingredient/Active Majety

Active ingredient/Active Molecty						
	Ingredient Name	<b>Basis of Strength</b>	Strength			
SULFACETAMIDE UNII:4965G3J0F5)	SODIUM (UNII: 4NRT660KJQ) (SULFACETAMIDE -	SULFACETAMIDE SODIUM	98 mg in 1 g			
SULFUR (UNII: 70FI	D1KFU70) (SULFUR - UNII:70FD1KFU70)	SULFUR	48 mg in 1 g			

Product Characteristics				
Color	yellow	Score		
Shape		Size		
Flavor		Imprint Code		
Contains				

P	Packaging						
#	Item Code	Package Description	Marketing Start Date	Marketing End Date			
1	NDC:52187-552- 60	60 in 1 CARTON	06/07/2021				
1	NDC:52187-552- 01	4 g in 1 PACKET; Type 0: Not a Combination Product					

Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
unapproved drug other		06/07/2021		

## Labeler - KMM Pharmaceuticals, LLC (078521761)

Revised: 12/2022 KMM Pharmaceuticals, LLC